• ABPI Website
  • Media Centre
  • Trust during turbulence – how does the pharmaceutical industry respond to the challenge of misinformation?

Trust during turbulence – how does the pharmaceutical industry respond to the challenge of misinformation?

Andy Collier, Senior Policy Manager for Reputation at the Association of the British Pharmaceutical Industry (ABPI), reflects on the ABPI’s recent event looking at how companies can help tackle mis- and disinformation.

Like so many other sectors, the pharmaceutical industry exists in an increasingly volatile and uncertain external environment. The health information landscape has changed substantially in recent years, accelerated by increased use of social media and AI. It is no longer the case that the physician-patient relationship is the only game in town. Information on both current and future medicines and vaccines is increasingly sought from a wide array of sources.

At the ABPI’s fourth annual Industry Summit, we discussed how the pharmaceutical industry can navigate this complex and fast-changing environment, how it can be an effective partner in existing efforts to address misinformation and how best to inspire trust through direct public engagement in science.

During each session, we considered how accurate and factual health information can cut through the noise and reach both patients and the public where they are.

The answer to this is of course not easy, but the call to action could not be clearer. Recent research delivered for the ABPI by Bryter conveys the scale of the current challenge. Eight in 10 GPs see patients coming to appointments with misinformation every week, with 68 per cent not fully confident in addressing it. It is a problem that many expect to get worse, with 98 per cent of GPs expecting patients’ use of AI to increase and 86 per cent expecting use of video-based social media to grow further.

Through the varied and insightful discussions on the day, there was a palpable appetite for more collaboration in efforts to address mis- and disinformation. A number of key themes were consistent across different topics:

Empower through direct engagement

Whether it is seeking out the views of younger generations or encouraging communities underrepresented in research to participate, trust can only grow when a direct connection exists. Embedding direct engagement in these activities, allowing opportunities for co-design and development, is essential to breaking down trust barriers.

Meet patients and the public where they are

In an era of information overload, supporting efforts to improve information literacy in isolation is not sufficient. Organisations active in this space must also prioritise algorithmic literacy and pursue multi-channel approaches to reach all audiences. This means paying equal attention to ‘how’ and ‘where’ messages are heard and not just ‘what’ is being conveyed.

Support trusted voices

Despite the challenges and changes emanating from the current health information environment, trust in established communicators remains resolute. The ABPI’s research with Bryter shows that official health communicators are the most trusted across all age groups by some distance, showing no signs of decline despite the availability of new sources. It is important that the pharmaceutical industry uses its expertise to equip these voices for a new and changing environment.

Emphasise transparency

For many, the complex and technical worlds of medicine and science are inaccessible. High levels of inaccessibility can lead to mistrust, which emboldens dissenting voices who claim that complexity is used to limit transparency. The science community, from industry and elsewhere, must be enabled to better explain the scientific journey for new medicines, involving equal emphasis on why new candidate medicines fail and why they succeed.

Mis- and disinformation are multifaceted challenges with potentially serious consequences for public health and patient outcomes. The only way to meet this challenge is through partnerships among those with the knowledge and expertise to aid the fight.

For pharmaceutical companies, the question should never be whether action should be taken but where and how it can be most effectively delivered. In today’s world, any space left can quickly become a void that is too often filled with misinformation. Industry cannot fill that space alone, and nor should it. But as part of a coalition of trusted voices, we can help make sure that accurate, balanced information makes it way to patients wherever and whenever they need it.

Note: The ABPI, The Faculty of Pharmaceutical Medicine and Patient Information Forum (PIF) will be publishing a joint report on health misinformation in 2027. It will offer a quantitative assessment of the impact of misinformation on both patients and healthcare professionals, using the stats from Bryter referenced above alongside a set of co-authored policy recommendations.

TAGS
  • Reputation

Last reviewed date: 16 November 2026

Next review date: 16 November 2029